Arch Oncology Secures $105M Series C

30 Apr, 2021

Arch Oncology Secures $105M Series C
Photo by Jade Bonavente on Unsplash

– Arch Oncology, a clinical-stage immuno-oncology company, has closed a $105m Series C financing co-led by Eventide Asset Management, Cowen Healthcare Investments and current investor 3×5 Partners.
– New investors in the round included Adage Capital Management, Point72 Asset Management, Avego Healthcare Capital, FMB Research and Broadfin Holdings.
– The company’s existing investors, including Roche Venture Fund, RiverVest Venture Partners, and Lightchain also participated in the round.

Biotechnology North America
Crunchbase icon

Content report

The following text will be sent to our editors: